Answers are grounded in this paper and cite their sources.
// Marta Cabezón 1, 2 , Joan Bargay 3 , Blanca Xicoy 1 , Olga García 4 , Josep Borrás 3 , Mar Tormo 5 , Sílvia Marcé 1 , Carme Pedro 6 , David Valcárcel 7 , Maria-José Jiménez 1 , Ramón Guàrdia 8 , Laura Palomo 4 , Salut Brunet 9 , Ferran Vall-Llovera 10 , Antoni Garcia 11 , Evarist Feliu 1 and Lurdes Zamora 1 ; On Behalf of the CETLAM Group 1 Hematology Service, ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain 2 Departament de Medicina, Universitat Autònoma de Barcelona, Badalona, Spain 3 Hematology Service, Hospital Son Llàtzer, Mallorca, Spain 4 Josep Carreras Leukemia Research Institute, Campus Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain 5 Hematology Service, Hospital Clínic de Valencia, Valencia, Spain 6 Hematology Service, Hospital del Mar, Barcelona, Spain 7 Hematology Service, Hospital Vall d’Hebron, Barcelona, Spain 8 Hematology Service, ICO Girona-Hospital Josep Trueta, Girona, Spain 9 Hematology Service, Hospital de Sant Pau, Barcelona, Spain 10 Hematology Service, Hospital Mútua de Terrassa, Terrassa, Spain 11 Hematology Service, Hospital Arnau de Vilanova, Lleida, Spain Correspondence to: Lurdes Zamora, email: lzamora@iconcologia.net Keywords: myelodysplastic syndromes; secondary acute myeloid leukemia; targeted deep sequencing; prognostic factors; 5-azacytidine Received: December 06, 2017 Accepted: March 05, 2018 Published: April 10, 2018 ABSTRACT Myelodysplastic syndromes (MDS) are stem cell disorders caused by various gene abnormalities. We performed targeted deep sequencing in 39 patients with high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-up (response and/or relapse), with the aim to define their mutational status, to establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) and/or may have impact on survival. Overall, 95% of patients harbored at least one mutation. TP53, DNMT3A and SRSF2 were the most frequently altered genes. Mutations in TP53 correlated with higher risk features and shorter overall survival (OS) and progression free survival (PFS) in univariate analysis. Patients with SRSF2 mutations were associated with better OS and PFS. Response rate was 55%; but we could not correlate the presence of TET2 and TP53 mutations with AZA response. Patients with sAML presented more variations than patients with high-risk MDS, and usually at relapse the number of mutations increased, supporting the idea that in advanced stages of the disease there is a greater genomic complexity. These results confirm that mutation analysis can add prognostic value to high-risk MDS and sAML patients, not only at diagnosis but also at follow-up.
No takes yet. Share an insight, caveat, or question.
Cabezón et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: